SLN124 granted Orphan Drug Designation by EMA for the treatment of β-Thalassemia
15 janv. 2019 07h00 HE
|
Silence Therapeutics
SLN124 granted Orphan Drug Designation by EMA for the treatment of β-Thalassemia January 15, 2019 LONDON, Silence Therapeutics, PLC (LON: SLN) (“Silence” or “the Company”) a leader in the discovery,...